Steps sought to activate domestic biosimilar development

The establishment of a regulatory pathway for biosimilars will be the first step in creating a market pathway for biosimilars, according to the Korea Food and Drug Administration.

In an information session on July 30, a KFDA official said the government will consider a broad range of policy measures to support local biosimilar development, while clearing the regulatory pathway.

He pointed...